{"id":1036305,"date":"2012-04-07T10:10:52","date_gmt":"2012-04-07T10:10:52","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/uncategorized\/bio-lauds-signing-of-jobs-act-into-law.php"},"modified":"2024-08-17T15:55:24","modified_gmt":"2024-08-17T19:55:24","slug":"bio-lauds-signing-of-jobs-act-into-law","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/bio-lauds-signing-of-jobs-act-into-law.php","title":{"rendered":"BIO Lauds Signing of JOBS Act into Law"},"content":{"rendered":"<p><p>    WASHINGTON--(BUSINESS WIRE)--  <\/p>\n<p>    The Biotechnology    Industry Organization expressed strong support for the    signing of the Jumpstart Our Business Startups (JOBS) Act into    law today.  <\/p>\n<p>    I was honored to witness the signing of the JOBS Act into law.    This legislation will make the pathway to capital formation    more attainable for small biotechnology companies, encouraging    American innovation by removing bureaucratic hurdles, stated    BIO President and CEO Jim Greenwood.  <\/p>\n<p>    The JOBS Act creates an on-ramp to the public market for    emerging growth companies, allowing them five years to focus on    conducting critical research that can lead to new therapies and    cures before having to divert funds to address bureaucratic    hurdles that cause unnecessary delays.  <\/p>\n<p>    Through the JOBS Act, emerging companies will be exempt for    their first five years on the public market from the compliance    burdens of Sarbanes-Oxley (SOX) Section 404(b), which studies    by the U.S. Securities and Exchange Commission (SEC) estimate cost    companies up to $2 million per year. The Act will also ease    private fundraising through an expansion of the eligibility    requirements for SEC Regulation A offerings and broaden the    investor base by reforming the SEC private shareholder limit    and SEC Regulation D.  <\/p>\n<p>    This law will incentivize and encourage capital formation for    small, emerging biotechnology companies that do not yet have    products on the market, Greenwood stated. By allowing    companies to focus their limited funds on research rather than    on compliance, it will speed the development of new cures and    treatments for patients living with debilitating diseases such    as cancer, diabetes, Parkinsons, and HIV\/AIDS.  <\/p>\n<p>    The American biotechnology industry thanks the    Congress and President Obama for the enactment of the JOBS    Act, concluded Greenwood.  <\/p>\n<p>    About BIO  <\/p>\n<p>    BIO represents more than 1,100 biotechnology companies,    academic institutions, state biotechnology centers and related    organizations across the United States and in more than 30    other nations. BIO members are involved in the research and    development of innovative healthcare, agricultural, industrial    and environmental biotechnology products. BIO also produces the    BIO International Convention, the worlds largest gathering of    the biotechnology industry, along with industry-leading    investor and partnering meetings held around the world. BIO    produces     BIOtech Now, an online portal and monthly newsletter    chronicling innovations transforming our world.     Subscribe to BIOtech Now.  <\/p>\n<p>    Upcoming BIO Events  <\/p>\n<\/p>\n<p>Read the original:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/bio-lauds-signing-jobs-act-204100440.html\" title=\"BIO Lauds Signing of JOBS Act into Law\" rel=\"noopener\">BIO Lauds Signing of JOBS Act into Law<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> WASHINGTON--(BUSINESS WIRE)-- The Biotechnology Industry Organization expressed strong support for the signing of the Jumpstart Our Business Startups (JOBS) Act into law today. I was honored to witness the signing of the JOBS Act into law.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/bio-lauds-signing-of-jobs-act-into-law.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246860],"tags":[],"class_list":["post-1036305","post","type-post","status-publish","format-standard","hentry","category-biotechnology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1036305"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1036305"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1036305\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1036305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1036305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1036305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}